These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18061317)

  • 1. Characterization of immunity induced by M2e of influenza virus.
    Wu F; Huang JH; Yuan XY; Huang WS; Chen YH
    Vaccine; 2007 Dec; 25(52):8868-73. PubMed ID: 18061317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge.
    Hashemi H; Pouyanfard S; Bandehpour M; Noroozbabaei Z; Kazemi B; Saelens X; Mokhtari-Azad T
    PLoS One; 2012; 7(9):e45765. PubMed ID: 23029232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.
    Zhao G; Lin Y; Du L; Guan J; Sun S; Sui H; Kou Z; Chan CC; Guo Y; Jiang S; Zheng BJ; Zhou Y
    Virol J; 2010 Jan; 7():9. PubMed ID: 20082709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
    Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
    Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
    Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
    Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine.
    Wu F; Yuan XY; Li J; Chen YH
    Vaccine; 2009 Jul; 27(32):4320-4. PubMed ID: 19410621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.
    Denis J; Acosta-Ramirez E; Zhao Y; Hamelin ME; Koukavica I; Baz M; Abed Y; Savard C; Pare C; Lopez Macias C; Boivin G; Leclerc D
    Vaccine; 2008 Jun; 26(27-28):3395-403. PubMed ID: 18511159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
    Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
    Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice.
    Alvarez P; Zylberman V; Ghersi G; Boado L; Palacios C; Goldbaum F; Mattion N
    Vaccine; 2013 Jan; 31(5):806-12. PubMed ID: 23246552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
    Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
    Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
    El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
    J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice.
    Li K; Luo J; Wang C; He H
    Vaccine; 2011 Oct; 29(44):7711-7. PubMed ID: 21839133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.
    Liu W; Zou P; Chen YH
    Immunol Lett; 2004 May; 93(2-3):131-6. PubMed ID: 15158608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
    Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
    Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.